LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 202631.3.2026 15:00:00 CEST | Press release
Boomi™, the data activation company, today announced it has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment, which evaluates vendors based on their capabilities and strategies for delivering API management solutions (APIM) in an increasingly AI-driven, hybrid enterprise landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331354139/en/ Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2026 As enterprises accelerate adoption of agentic AI and hybrid architectures, the need to govern and scale APIs across increasingly complex environments has become a strategic priority. APIs are central to enabling secure, reusable, and agent-ready access to applications and data. Boomi’s API management solution, with an enterprise-grade gateway and advanced federation capabilities, enables organizations to design, secure, and manage APIs seamlessly across distributed runt
Lotte Rental Speeds Growth and Innovation with Multiyear Partnership with Rimini Street31.3.2026 15:00:00 CEST | Press release
South Korea’s top car rental company cuts IT costs, boosts flexibility and powers digital transformation with long-term savings and robust services powered by Rimini Support™ for SAP and Oracle Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Lotte Rental, South Korea’s leading car rental company, has selected Rimini Street to provide support for its Oracle and SAP systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331863399/en/ Lotte Rental Speeds Growth and Innovation with Multiyear Partnership with Rimini Street A leader in the rental industry for over 40 years, Lotte Rental operates 300 branches across Korea and subsidiaries in Thailand and Vietnam and offers car sharing and used car sales. To drive its vision of accelerating growth and staying ahead in the mobility industry,
Driscoll’s Names Wadih J. Khayat Chief Financial Officer31.3.2026 15:00:00 CEST | Press release
Driscoll’s, the world’s leading fresh berry company, announced Wadih J. Khayat has joined the company as chief financial officer. Reporting to Driscoll’s CEO Soren Bjorn, Khayat will oversee global finance, technology and strategy. He will work closely with regional and functional leaders to ensure disciplined capital deployment and the long-term success of the company’s global network of independent growers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331858044/en/ Khayat is a strategic finance executive and transformational change leader with deep global experience and a strong record of delivering results at scale. He joins Driscoll’s from The Coca-Cola Co., where he spent more than two decades leading major finance organizations worldwide. Most recently, he served as senior vice president and CFO for Coca-Cola’s Europe business, overseeing operations across 38 countries. He previously held senior leadership roles w
Convera Joins Forces with Ripple to Empower Stablecoin-Enabled Cross-Border Payments31.3.2026 15:00:00 CEST | Press release
Convera, a global leader in commercial payments, today announced a new strategic collaboration with Ripple, a leading provider of blockchain-based enterprise solutions across traditional and digital finance, to offer crypto-enabled payment and treasury solutions for businesses. “With the growing presence and use of digital currencies such as crypto and stablecoins, Convera has maintained a thoughtful approach by listening to what our customers want while watching this space continue to mature. We knew we needed a trusted, visionary partner that can help us meet our customers where they are in their journey,” said Patrick Gauthier, CEO, Convera. “Ripple is a clear leader in the crypto space and a natural fit for Convera. We look forward to continued success and growth as we roll out these capabilities to customers near and far.” Convera’s partnership with Ripple brings together two industry leaders to enhance global payments through stablecoin and blockchain infrastructure. By combining
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom